Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital
-
- Goto Hisatsugu
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Hanibuchi Masaki
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Sakaguchi Satoshi
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Kanematsu Takanori
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Kakiuchi Soji
- Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Tomimoto Hideki
- Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Azuma Masahiko
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Tezuka Toshifumi
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Tada Hiroya
- Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Miki Yukiyo
- Outpatient Chemotherapy Unit, Tokushima University Hospital
-
- Nakamura Toshimi
- Outpatient Chemotherapy Unit, Tokushima University Hospital
-
- Sone Saburo
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
-
- Nishioka Yasuhiko
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
この論文をさがす
説明
Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy, respectively, are shown to prolong the survival of lung cancer patients in various randomized phase III studies. However, the evidence for the efficacy of chemotherapy for lung cancer in the clinical practice is still insufficient. In the present study, we investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were 55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients were found to decrease substantially with each line of treatment as described previously. All adverse events were well tolerated and no treatment-related death was observed. Median time to treatment failures (TTFs) of first-line treatment were 10.1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management. J. Med. Invest. 58: 219-226, August, 2011
収録刊行物
-
- The Journal of Medical Investigation
-
The Journal of Medical Investigation 58 (3,4), 219-226, 2011
国立大学法人 徳島大学医学部
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204242990976
-
- NII論文ID
- 130004822660
- 80021963489
-
- NII書誌ID
- AA11166929
-
- ISSN
- 13496867
- 13431420
-
- PubMed
- 21921423
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- IRDB
- Crossref
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可